Science Spotlight.Some NIDA-funded scientists have just published findings in the journal Science showing the development of a new, groundbreaking chemogenetics technology for modulating brain function in a remote, precise and ultra-sensitive manner in living subjects.
The scientific world has advanced immeasurably by the science of DNA and genetics. Manipulating gene expression to change the way that cells such as neurons function has helped scientists create very specific tools to use for understanding and developing treatments for human diseases.
Study results on long-acting injection formulation now published.
A newly published study suggests the long-acting buprenorphine formulation BUP-XR is more effective than placebo in helping patients struggling with addiction to opioids. BUP-XR is a monthly extended-release injection.
As we enter 2019, it is a good time to take stock of what NIDA accomplished over the past year. As always when I look back at the research being done by NIDA grantees and partners, I am amazed at the wealth of knowledge being created from our investments. Here I want to highlight just a few of the many outstanding developments in basic science, new therapeutics, and epidemiology and prevention research from the year that just ended.
Opioid misuse at record lows with marijuana use remaining stable.
America’s teens report a dramatic increase in their use of vaping devices in just a single year, with 37.3 percent of 12th graders reporting “any vaping” in the past 12 months, compared to just 27.8 percent in 2017.
The National Institutes of Health announced today that enrollment for the Adolescent Brain Cognitive Development (ABCD) Study is now complete and, in early 2019, scientists will have access to baseline data from all ABCD Study participants.
The National Institute on Drug Abuse (NIDA) today announced the availability of informational resources for clinicians interested in initiating buprenorphine treatment in emergency department settings.
Nicotine does not produce the kind of euphoria or impairment that many other drugs like opioids and marijuana do. People do not get high from smoking cigarettes or vaping. Yet nicotine’s powerful ability to reinforce its relatively mild rewards results in 480,000 deaths annually.
The public health emergency of opioid misuse and addiction affects millions of Americans and requires innovative scientific solutions. Today, during “National Prescription Opioid and Heroin Awareness Week,” we are sharing news of an important step towards these solutions through the HEALing Communities Study.
Ample evidence shows methadone and buprenorphine reduce overdose deaths, prevent the spread of diseases like HIV, and enable people to take back their lives, but there are restrictions on who can prescribe these medications.
An analysis of health data concludes that e-cigarette use, adjusted for smoking conventional cigarettes and other risk factors, is associated with increased risk of myocardial infarction, which is commonly known as a heart attack caused by blockage of the arteries.
The National Institute on Drug Abuse (NIDA) Clinical Trials Network has unveiled a new scientifically validated, online screening tool designed to assess a patient’s risk for substance misuse and substance use disorder, and assist the health care provider with prevention and treatment strategies.
New online course is 10th in a series developed by the NIH Pain Consortium.
A case-based clinician training module designed for the evaluation of acute pain and opioid management for adults is now available through the Centers of Excellence in Pain Education (CoEPE) program, coordinated by the National Institute on Drug Abuse.
A comprehensive analysis of health insurance coverage of non-opioid and opioid medications to treat chronic low back pain concluded that some insurance plans have missed important opportunities to steer patients towards safer and more effective treatments than prescription opioids.
NIH research confirms effective treatments for opioid use disorder are underutilized.
A National Institutes of Health-funded study found that treatment of opioid use disorder with either methadone or buprenorphine following a nonfatal opioid overdose is associated with significant reductions in opioid related mortality.
In spring 2018, Congress added an additional $500 million to the NIH budget to invest in science to find solutions to the opioid crisis. The funding that NIDA is receiving will go toward the goal of addressing addiction in new ways and better delivering existing forms of care to populations that need it.
The special issue is an overview of the ABCD Study and includes articles about the rationale for the study, its design and recruitment strategy, assessment protocols and neuroimaging parameters, the inclusion of twins in the research design, biomedical ethics and clinical oversight, and retention considerations, among others.